UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy (2024)

Table of Contents
References Acknowledgements CETLAM Group Author information Authors and Affiliations Consortia on the behalf of CETLAM Group Corresponding author Ethics declarations Conflict of interest Additional information Supplementary information Suppl. Table 1 Suppl. Figure 1 Suppl. Figure 2 Rights and permissions About this article Cite this article

References

  1. Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 2002;16:1699–704.

    Article CAS Google Scholar

  2. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–66.

    Article CAS Google Scholar

  3. Hyo Kim L, Sub Cheong H, Koh Y, Ahn KS, Lee C, Kim HL, et al. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. J Hum Genet. 2015;60:749–54.

    Article CAS Google Scholar

  4. Yee SW, Mefford JA, Singh N, Percival ME, Stecula A, Yang K, et al. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013;58:353–61.

    Article CAS Google Scholar

  5. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature 2014;511:90–3.

    Article CAS Google Scholar

  6. Zahreddine HA, Borden KL. Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells. Clin Cancer Res. 2015;21:2207–10.

    Article CAS Google Scholar

  7. Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden KLB. GLI1-Inducible glucuronidation targets a broad spectrum of drugs. ACS Chem Biol. 2019;14:348–55.

    Article CAS Google Scholar

  8. Guillemette C, Lévesque É, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharm Ther. 2014;96:324–39.

    Article CAS Google Scholar

  9. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998;95:8170–4.

    Article CAS Google Scholar

  10. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.

    Article CAS Google Scholar

  11. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–35.

    Article CAS Google Scholar

  12. Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106:3618–20.

    Article CAS Google Scholar

  13. Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624–33.

    Article Google Scholar

  14. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6.

    CAS PubMed Google Scholar

  15. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382–8.

    Article CAS Google Scholar

  16. de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist. 2006;11:944–54.

    Article Google Scholar

  17. Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharm. 1995;36:425–30.

    Article CAS Google Scholar

  18. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995;333:1171–5.

    Article CAS Google Scholar

  19. Schwartz JB. The influence of sex on pharmaco*kinetics. Clin Pharmaco*kinet. 2003;42:107–21.

    Article CAS Google Scholar

  20. Jeong H, Choi S, Song JW, Chen H, Fischer JH. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 2008;38:62–75.

    Article CAS Google Scholar

  21. Chen P, Zhu KW, Zhang DY, Yan H, Liu H, Liu YL, et al. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens. J Transl Med. 2018;16:197.

    Article CAS Google Scholar

Download references

Acknowledgements

This study has been financed in part by grant Oncotrail (Oncolliga Girona) and by grant Llavaneres contra el Càncer.

CETLAM Group

Jorge Sierra, Jordi Esteve, Josep M. Ribera, David Gallardo, Joan Bargay, Olga Salamero, Mar Tormo, Montserrat Arnán, Antònia Sampol, Rosa Coll, Johana Díaz-Santa, Natàlia Lloveras, David Cruz, Carla Moret, Teresa Quiñones, Marina Díaz-Beya, Àlex Bataller, Dolors Costa, María Rozman, Neus Villamor, Francisca Guijarro, Marta Pratcorona, Ana Garrido, Montserrat Hoyos Colell, Marisa Calabuig, Mª Salut Brunet Mauri, Josep F. Nomdedeu, Josep M. Martí-Tutusaus, Ferran Vall.llovera, Marta Canet, Carme Pedro, Leonor Arenillas, Xavier Calvo, Carlos Palacio, Bárbara Tazón, Ester Alonso, Helena Pomares, Susanna Vives, Blanca Xicoy, Lurdes Zamora, Isabel Granada, Marta Cabezón, Francesc Solé, Marcus Buschbeck, Lourdes Escoda, M. Carme Talarn, Marta Cervera, Vicent Castelló, M. Teresa Giménez, Granada Perea, Elena Rámila, M. Luz Muñoz, Marta Gómez, Antoni García-Guiñón, M. Eugènia Rivero, Eva Villamón, Inma Heras, Antonia Cladera, Jordi Martínez, Xavier Ortín, Cristina Motlló.

Author information

Authors and Affiliations

  1. Hematology Department, Catalan Institute of Oncology (ICO), Girona. Institut d’Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, Girona, Spain

    Johana Díaz-Santa,Rocío Rodríguez-Romanos,Gemma Osca,Rosa Coll,Carla Moret,Natàlia Lloveras,David Cruz,Teresa Quiñones&David Gallardo

    See Also
    UGT1A1 (TA)n Promoter Genotype: Diagnostic and Population Pharmacogenetic Marker in SerbiaUGT1A1 gene: MedlinePlus GeneticsUGT1A1 genotyping for Gilbert Syndrome - Clinical Genetic Test - GTRGenetic testing of UGT1A1 in the diagnosis of Gilbert syndrome: The discovery of seven novel variants in the Chinese population

  2. Hematology Department, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

    Marta Pratcorona,Ana Garrido&Jorge Sierra

  3. Hematology Department, Catalan Institute of Oncology (ICO), Hospital Joan XXIII, Tarragona, Spain

    Lourdes Escoda

  4. Hematology Department, Hospital Clínico, Valencia, Spain

    Mar Tormo

  5. Department of Hematology, University Hospital Morales Meseguer, Murcia, Spain

    Inma Heras

  6. Department of Hematology, Catalan Institute of Oncology (ICO), L’Hospitalet, Barcelona, Spain

    Montse Arnan

  7. Hematology Department, Catalan Institute of Oncology (ICO), Badalona, Josep Carreras Leukemia Research Institute (IJC), Badalona, Barcelona, Spain

    Susanna Vives

  8. Hematology Department, Hospital Vall d’Hebró, Barcelona, Spain

    Olga Salamero

  9. Hematology Department, Hospital de Son Llàtzer, Palma de Mallorca, Spain

    Joan Bargay

  10. Hematology Department, Hospital Son Espases, Palma de Mallorca, Spain

    Antònia Sampol

  11. Hematology Department, Hospital Arnau de Vilanova, Lleida, Spain

    Antoni Garcia

  12. Hematology Department, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

    Jordi Esteve

Authors

  1. Johana Díaz-Santa

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  2. Rocío Rodríguez-Romanos

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  3. Gemma Osca

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  4. Marta Pratcorona

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  5. Ana Garrido

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  6. Rosa Coll

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  7. Carla Moret

    View author publications

    You can also search for this author in PubMedGoogle Scholar

    See Also
    UGT1A1 Gene Analysis | Test Fact Sheet
  8. Lourdes Escoda

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  9. Mar Tormo

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  10. Inma Heras

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  11. Montse Arnan

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  12. Susanna Vives

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  13. Olga Salamero

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  14. Natàlia Lloveras

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  15. Joan Bargay

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  16. Antònia Sampol

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  17. David Cruz

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  18. Antoni Garcia

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  19. Teresa Quiñones

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  20. Jordi Esteve

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  21. Jorge Sierra

    View author publications

    You can also search for this author in PubMedGoogle Scholar

  22. David Gallardo

    View author publications

    You can also search for this author in PubMedGoogle Scholar

Consortia

on the behalf of CETLAM Group

Corresponding author

Correspondence to David Gallardo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Members of the CETLAM Group are listed below Acknowledgements

Rights and permissions

About this article

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy (1)

Cite this article

Díaz-Santa, J., Rodríguez-Romanos, R., Osca, G. et al. UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Leukemia 34, 2925–2933 (2020). https://doi.org/10.1038/s41375-020-0784-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-0784-2

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy (2024)
Top Articles
How Chenin Blanc Charmed Wine Experts
Chenin Blanc wine guide - Wine Dharma
Understand the architecture of CNN
Gwyn
Latest Posts
Premium: Definition, Meanings in Finance, and Types
What are insurance premiums?
Article information

Author: Jerrold Considine

Last Updated:

Views: 5494

Rating: 4.8 / 5 (78 voted)

Reviews: 93% of readers found this page helpful

Author information

Name: Jerrold Considine

Birthday: 1993-11-03

Address: Suite 447 3463 Marybelle Circles, New Marlin, AL 20765

Phone: +5816749283868

Job: Sales Executive

Hobby: Air sports, Sand art, Electronics, LARPing, Baseball, Book restoration, Puzzles

Introduction: My name is Jerrold Considine, I am a combative, cheerful, encouraging, happy, enthusiastic, funny, kind person who loves writing and wants to share my knowledge and understanding with you.